Molecular Mechanisms in Allergy and Clinical ImmunologyCyclic nucleotide phosphodiesterases☆,☆☆
Section snippets
Classification and structural biology
Table I shows the current classification scheme for cyclic nucleotide PDEs. Eleven distinct families (or types) are differentiated functionally on the basis of substrate specificity and sensitivity to endogenous/exogenous regulators and genetically on the basis of sequence homology (3 additional families have been reported, but the data available at this time are insufficient for their inclusion in Table I).13, 14, 15, 16, 17 Most of the families include more than 1 gene product (subtype,
Pharmacology
The general schema for the formation and degradation of cyclic nucleotides is depicted in Fig 1.
In vitro effects
Inflammatory cells are exquisitely sensitive to alterations in cyclic nucleotide levels; interestingly, modulation of immune cell function by selective PDE inhibitors is limited to specific PDE types, probably as a result of compartmentalization of cyclic nucleotide and PDE pools. In immune cells, elevation of intracellular cAMP, mediated predominantly through inhibition of PDE4, results in a wide range of anti-inflammatory effects, as summarized in Table II.
In vivo effects
PDE inhibitors have been evaluated as potential antidepressants, anti-inflammatory agents, antiproliferative agents, antihypertensive and cardiovascular agents, and cytoprotective agents.13, 116, 117, 118, 119, 120 To date, clinical development of selective PDE inhibitors has focused primarily on PDE3, PDE4, and PDE5. Despite early promise, clinical development of PDE3 inhibitors for congestive heart failure was essentially abandoned because of a concomitant increase in the incidence of cardiac
Conclusions
The past several years have witnessed significant advances in our understanding of the molecular pharmacology of cyclic nucleotide PDEs. With the advent of second-generation PDE4 inhibitors, the continued success of PDE5 inhibitors, and recent advances in rational structure/function drug design, the therapeutic promise of selective PDE inhibitors may soon be realized.
Acknowledgements
I would like to thank Drs Susan Jerian, Richard McFarland, and Mercedes Sirabian for their review of the manuscript. I would also like to thank Ms Jacqueline Schaffer for her concept and rendering of Fig 1.
References (142)
- et al.
Fractionation and characterization of a cyclic adenine ribonucleotide formed by tissue particles
J Biol Chem
(1958) - et al.
Hydrolysis of cyclic guanosine and adenosine 3′,5′-monophosphates by rat and bovine tissues
J Biol Chem
(1970) - et al.
Cyclic nucleotide phosphodiesterases: relating structure and function
Prog Nucleic Acid Res Mol Biol
(2000) - et al.
The molecular biology of cyclic nucleotide phosphodiesterases
Prog Nucleic Acid Res Mol Biol
(1999) Cyclic nucleotide phosphodiesterase (PDE) inhibitors and immunomodulation
Biochem Pharmacol
(1999)- et al.
Identification and characterization of a novel family of cyclic nucleotide phosphodiesterases
J Biol Chem
(1998) - et al.
ERK2 mitogen-activated protein kinase binding, phosphorylation, and regulation of the PDE4D cAMP-specific phosphodiesterases. The involvement of COOH-terminal docking sites and NH2-terminal UCR regions
J Biol Chem
(2000) - et al.
Phosphorylation and activation of a cAMP-specific phosphodiesterase by the cAMP-dependent protein kinase. Involvement of serine 54 in the enzyme activation
J Biol Chem
(1996) - et al.
Activation of the cAMP-specific phosphodiesterase PDE4D3 by phosphorylation. Identification and function of an inhibitory domain
J Biol Chem
(1999) - et al.
Zinc dependent activation of cAMP-specific phosphodiesterase (PDE4A)
Biochem Biophys Res Commun
(1997)
Structure, mechanism, and regulation of mammalian adenyl-yl cyclase
J Biol Chem
Salbutamol up-regulates PDE4 activity and induces a heterologous desensitization of U937 cells to prostaglandin E2. Implications for the therapeutic use of beta-adrenoceptor agonists
J Biol Chem
Requirement of additional adenylate cyclase activation for the inhibition of human eosinophil degranulation by phosphodiesterase IV inhibitors
Eur J Pharmacol
Subcellular localization of rolipram-sensitive, cAMP-specific phosphodiesterases. Differential targeting and activation of the splicing variants derived from the PDE4D gene
J Biol Chem
Rapid regulation of PDE-2 and PDE-4 cyclic AMP phosphodiesterase activity following ligation of the T cell antigen receptor on thymocytes: analysis using the selective inhibitors erythro-9-(2-hydroxy-3-nonyl)-adenine (EHNA) and rolipram
Cell Signal
Cyclic GMP-dependent protein kinases: understanding in vivo functions by gene targeting
Pharmacol Ther
AKAPs: from structure to function
Trends Cell Biol
The scaffold protein gravin (cAMP-dependent protein kinase-anchoring protein 250) binds the beta 2-adrenergic receptor via the receptor cytoplasmic Arg-329 to Leu-413 domain and provides a mobile scaffold during desensitization
J Biol Chem
Characterization of distinct tethering and intracellular targeting domains in AKAP75, a protein that links cAMP-dependent protein kinase II beta to the cytoskeleton
J Biol Chem
Signaling pathways for antigen receptor-mediated induction of transcription factor CREB in B lymphocytes
Cell Immunol
Studies of the intracellular Ca2+ levels in human adult skin mast cells activated by the ligand for the human c-kit receptor and anti-IgE
Biochem Pharmacol
LY 186655, a phosphodiesterase inhibitor, inhibits histamine release from human basophils, lung and skin fragments
Int J Immunopharmacol
Role of cyclic 3′,5′-adenosine monophosphate in the regulation of chemical mediator release and cytokine production from cultured human mast cells
J Allergy Clin Immunol
Phosphodiesterase profiles of highly purified human peripheral blood leukocyte populations from normal and atopic individuals: a comparative study
J Allergy Clin Immunol
Effects of a selective PDE4 inhibitor, D-22888, on human airways and eosinophils in vitro and late phase allergic pulmonary eosinophilia in guinea pigs
Pulm Pharmacol Ther
Elevated intracellular cyclic AMP inhibits chemotaxis in human eosinophils
Cell Signal
Role of cyclic nucleotides and nitric oxide in blood mononuclear cell IgE production stimulated by IL-4
Cytokine
Interleukin-4 overcomes the negative influence of cyclic AMP accumulation on antigen receptor stimulated B lymphocytes
Mol Immunol
Phosphodiesterase inhibition by Ro 20-1724 reduces hyper-IgE synthesis by atopic dermatitis cells in vitro
J Invest Dermatol
Increased interleukin-4 production by atopic mononuclear leukocytes correlates with increased cyclic adenosine monophosphate-phosphodiesterase activity and is reversible by phosphodiesterase inhibition
J Invest Dermatol
Multiple high-affinity cAMP-phosphodiesterases in human T-lymphocytes
Biochem Pharmacol
Regulation of interleukin-13 by type 4 cyclic nucleotide phosphodiesterase (PDE) inhibitors in allergen-specific human T lymphocyte clones
Biochem Pharmacol
Rolipram inhibits staphylococcal enterotoxin B-mediated induction of the human skin-homing receptor on T lymphocytes
J Invest Dermatol
Characterization of the phosphodiesterase (PDE) pattern of in vitro-generated human dendritic cells (DC) and the influence of PDE inhibitors on DC function
Pulm Pharmacol Ther
Interactions between cAMP- and cGMP-dependent protein kinase inhibitors and phosphodiesterase IV inhibitors on arachidonate release from human monocytes
Life Sci
Characterization of cAMP-dependent inhibition of LPS-induced TNF alpha production by rolipram, a specific phosphodiesterase IV (PDE IV) inhibitor
Int J Immunopharmacol
Effects of cAMP-phosphodiesterase isozyme inhibitor on cytokine production by lipopolysaccharide-stimulated human peripheral blood mononuclear cells
Gen Pharmacol
Interactions of formylmethionyl-leucyl-phenyl-alanine, adenosine, and phosphodiesterase inhibitors in human monocytes. Effects on superoxide release, inositol phosphates and cAMP
FEBS Lett
The 100 top brands
Business Week
On the medical history of xanthines and other remedies for asthma: a tribute to HH Salter
Thorax
The properties of an adenine ribonucleotide produced with cellular particles, ATP, Mg++, and epinephrine or glucagon
J Am Chem Soc
The role of cyclic AMP in the cytolytic activity of lymphocytes
J Immunol
The role of cyclic 3′,5′ adenosine monophosphate in the specific cytolytic activity of lymphocytes
J Immunol
Modulation of inflammation and immunity by cyclic AMP
Science
Effects of xanthine derivatives on lipolysis and on adenosine 3′,5′-monophosphate phosphodiesterase activity
Mol Pharmacol
Inhibition of separated forms of cyclic nucleotide phosphodiesterase from pig coronary arteries by 1,3-disubstituted and 1,3,8-trisubstituted xanthines
J Med Chem
Cloning and characterization of a cAMP-specific cyclic nucleotide phosphodiesterase
Proc Natl Acad Sci U S A
Isolation and characterization of a dual-substrate phosphodiesterase gene family: PDE10A
Proc Natl Acad Sci U S A
Cloning and characterization of two splice variants of human phosphodiesterase 11A
Proc Natl Acad Sci U S A
Characterization of five different proteins produced by alternatively spliced mRNAs from the human cAMP-specific phosphodiesterase PDE4D gene
Biochem J
Cited by (387)
Phosphodiesterase 4 activity uniquely regulates ciliary cAMP-dependent 3T3-L1 adipogenesis
2024, Cellular SignallingThe effect of PACAP administration on LPS-induced cytokine expression in the Atlantic salmon SHK-1 cell line.
2023, Fish and Shellfish Immunology ReportsA purine derivative, paraxanthine, promotes cysteine uptake for glutathione synthesis
2023, Journal of Pharmacological SciencesNonclinical genotoxicity and carcinogenicity profile of apremilast, an oral selective inhibitor of PDE4
2021, Regulatory Toxicology and PharmacologyThromboxane-induced cerebral microvascular rarefaction predicts depressive symptom emergence in metabolic disease
2024, Journal of Applied Physiology
- ☆
The opinions expressed are those of the author and are not necessarily those of the US Food and Drug Administration.
- ☆☆
Reprint requests: David M. Essayan, MD, DCTDA, OTRR, CBER, USFDA, 1401 Rockville Pike, HFM-579, Rockville, MD 20852.